Condition 1: Polycystic ovarian syndrome. Condition 2: Overweight and obesity. Polycystic ovarian syndrome Overweight and obesity
Conditions
Interventions
Intervention 1: People in this group will recieve three 500 mg capsules of licorice daily for 8 weeks. Intervention 2: Control group: People in this group will recieve three 500 mg capsules of placebo
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Age between 18 to 45 BMI 25-35 kg/m2 Polycystic ovary syndrome based on Rotterdam criteria
Exclusion criteria
Exclusion criteria: Blood pressure equal or than 90/140 mmHg Cardiovascular diseases with regular drug use, liver, kidney and thyroid disorders, diabetes Taking multi vitamin-mineral supplements Smoking Antioxidant and herbal treatments during the last 3 months Pregnancy and lactation Consumption of licorice more than 300 grams per week Hyper androgenism includes hereditary adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and hypothyroidism or androgen-secreting tumors History of allergy to licorice or any of its components
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum testosterone level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum SHBG level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.;Serum FSH level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.;Serum LH level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.;Serum insulin level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.;Serum FBS level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.;Serum LDL level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.;Serum HDL level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.;Serum TG level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.;Serum Cholesterol level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.;BDI questionnaire. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Likert scale.;Pittsburgh Sleep Quality Index (PSQI). Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Likert scale.;The Council on Nutrition Appetite Questionnaire (CNAQ). Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Likert scale.;Body composition. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Body analyzer.;Anthropometric measurements (height, weight, BMI, waist circumference, hip circumference, abdominal / hip ratio). Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Body analyzer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHadis Hooshmandi
Yazd University of Medical Sciences
Outcome results
None listed